EP 3558354 A1 20191030 - LASSA VIRUS VACCINE
Title (en)
LASSA VIRUS VACCINE
Title (de)
IMPFSTOFF GEGEN DAS LASSA-VIRUS
Title (fr)
VACCIN CONTRE LE VIRUS DE LASSA
Publication
Application
Priority
- EP 2016082605 W 20161223
- EP 2017084562 W 20171222
Abstract (en)
[origin: WO2018115525A1] The present invention provides mRNAs usable as vaccines against lassa virus (LASV) infections. Further, the invention relates to (pharmaceutical) compositions and vaccines comprising said mRNAs and their use for treatment or prophylaxis of a lassa virus infection. The present invention further features a kit comprising the mRNAs, (pharmaceutical) compositions or vaccines and a method for treatment or prophylaxis of lassa virus infections using said mRNAs, pharmaceutical) compositions or vaccines.
IPC 8 full level
A61K 39/12 (2006.01); A61P 31/14 (2006.01); C12N 7/00 (2006.01)
CPC (source: EP US)
A61K 39/12 (2013.01 - EP US); A61P 31/14 (2017.12 - EP US); C07K 14/005 (2013.01 - EP US); C12N 7/00 (2013.01 - US); A61K 2039/53 (2013.01 - EP US); A61K 2039/54 (2013.01 - US); C12N 2760/10022 (2013.01 - EP US); C12N 2760/10034 (2013.01 - EP US); C12N 2830/50 (2013.01 - EP US)
Citation (search report)
See references of WO 2018115525A1
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
WO 2018115525 A1 20180628; EP 3558354 A1 20191030; US 11464847 B2 20221011; US 2019351044 A1 20191121; US 2023181713 A1 20230615
DOCDB simple family (application)
EP 2017084562 W 20171222; EP 17832966 A 20171222; US 201716471544 A 20171222; US 202217930065 A 20220906